SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS) today announced that it has entered into a strategic collaboration with Cosmo Technologies Limited (Cosmo), a wholly owned subsidiary of Cosmo Pharmaceuticals SpA (SIX:COPN), which grants Santarus exclusive rights to develop and commercialize Budesonide MMX® and Rifamycin SV MMX® for the U.S. market. Terms of the agreements include an upfront payment to Cosmo of cash and Santarus common stock, shared development costs, clinical/regulatory and commercial milestones and a royalty on net sales, as more fully described below.
